 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.236.933  |
| Chemical and physical data | |
| Formula | C19H26O2 |
| Molar mass | 286.415 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry)ofcannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units).
Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.[1]=[2][3]
CBDV demonstrated anticonvulsant in rodent models in a single published study.[4] It was identified for the first time in 1969 by Vollner et al.[5]
Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.[7] GW has begun several Phase-2 trials for adult epilepsy,[8] for childhood epilepsy and for Prader-Willi Syndrome.[9][10]
|
| |||||
|---|---|---|---|---|---|
| TRPA |
| ||||
| TRPC |
| ||||
| TRPM |
| ||||
| TRPML |
| ||||
| TRPP |
| ||||
| TRPV |
| ||||
See also: Receptor/signaling modulators • Ion channel modulators | |||||
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
